제리스 바이오파마 홀딩스, Inc.
DE ˙ DB ˙ US98422E1038
€5.20 ↑0.22 (4.40%)
2026-06-05
주가
SecurityDE:2B30 / Xeris Biopharma Holdings, Inc.
InstitutionXTX Topco Ltd
Latest Disclosed Ownership20,272 shares
Latest Disclosed Value $ 117,578
XTX Topco Ltd ownership in 2B30 / Xeris Biopharma Holdings, Inc.

On May 15, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 20,272 shares of Xeris Biopharma Holdings, Inc. (DE:2B30) valued at $97,752 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of Xeris Biopharma Holdings, Inc.. The current value of the position is $105,414 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 20,272 20,272 118 0.0020
2025-11-14 2025-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 0 -24,662 -100.00 0 -100.00
2025-08-12 2025-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 24,662 -191,566 -88.59 115 -90.31 0.0048
2025-05-08 2025-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 216,228 216,228 1,187 0.0607
2025-02-13 2024-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 0 -13,890 -100.00 0 -100.00
2024-11-14 2024-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 13,890 -17,892 -56.30 40 -45.07 0.0029
2024-08-12 2024-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 31,782 -223,267 -87.54 72 -87.39 0.0061
2024-05-13 2024-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 255,049 238,563 1,447.06 564 1,381.58 0.0760
2024-02-13 2023-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 16,486 16,486 39 0.0085
2023-08-14 2023-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 0 -233,385 -100.00 0 -100.00
2023-05-12 2023-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 233,385 44,474 23.54 380 51.39 0.0797
2023-02-14 2022-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 188,911 188,911 251 0.0533
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.